Gupta M K, Chiang T, Deodhar S D
Acta Endocrinol (Copenh). 1983 May;103(1):76-80. doi: 10.1530/acta.0.1030076.
The effect of T4 treatment (40 micrograms, 5 times/week) on immune function in C57Bl/6J mice was studied. The primary antibody synthesis as measured by the plaque-forming cell (PFC) assay demonstrated significant suppression in mice treated with T4 for 30 days. Mitogen assays using PHA and Con A demonstrated significant suppression of cellular immune responses as measured by [3H]thymidine incorporation. The effect was reversed when the treatment was discontinued and a normal response reappeared after 14 days. Allogeneic skin grafts (donor A/J mice) showed prolonged survival (median survival time, 13.5 days) in T4-treated mice as compared to control untreated mice (median survival time, 11 days). Further experiments using Chromium 51 assay for delayed type hypersensitivity also showed suppressed response. These results suggest that treatment with T4, in the above doses and duration, cause immunosuppression in C57Bl/6J mice.
研究了 T4 治疗(40 微克,每周 5 次)对 C57Bl/6J 小鼠免疫功能的影响。通过空斑形成细胞(PFC)试验测定的初次抗体合成显示,接受 T4 治疗 30 天的小鼠中有显著抑制。使用 PHA 和 Con A 的丝裂原试验显示,通过[3H]胸腺嘧啶核苷掺入测定,细胞免疫反应有显著抑制。当停止治疗时,这种作用会逆转,14 天后会重新出现正常反应。与未治疗的对照小鼠(中位存活时间为 11 天)相比,同种异体皮肤移植(供体为 A/J 小鼠)在接受 T4 治疗的小鼠中显示出更长的存活时间(中位存活时间为 13.5 天)。使用铬 51 试验进行迟发型超敏反应的进一步实验也显示反应受到抑制。这些结果表明,以上述剂量和持续时间进行 T4 治疗会导致 C57Bl/6J 小鼠免疫抑制。